The bandages Welly sells come in illustrated tins, priced above the store brand and stacked in the first-aid aisle as though they were greeting cards. That packaging won the brand shelf space at Target and other mass retailers, and it helped persuade Unilever to buy the company a few years ago. Unilever has now decided the brand belongs somewhere else.
Unilever has signed an agreement to sell Welly Health PBC to Forward Consumer Partners, a U.S. mid-market private-equity firm, the companies said. The transaction is expected to close in the fourth quarter of 2026. Neither side disclosed the price.
Two people familiar with the matter said the deal sits inside Forward’s stated range for control investments, which runs from $25 million to $250 million of enterprise value. Given the size of the brand, the likely enterprise value is under $100 million, according to one of those people, who cautioned that the figure will move with working-capital adjustments before closing.
For Eric Ryan, Welly’s co-founder, the sale closes a circle. Ryan started the brand in 2018, five years after selling Olly, his gummy-vitamin company, to Unilever. Welly was an attempt to run the same playbook on a category that had not changed in decades: take a commodity, restyle it, charge more, and put it where younger shoppers already walk.
Under Unilever the brand got distribution and manufacturing reach. What it did not get, according to people close to the business, was a permanent place in a portfolio that has been getting steadily smaller.
Ryan will return to Welly’s board as an adviser once the deal closes. He will not run the company. That arrangement was part of the negotiation from the start, people familiar with the plan said: Forward wanted the founder’s retail relationships and product instincts without handing him the chief executive’s chair.
Forward is a young firm, founded in 2023, with about $925 million in committed capital. This is its eighth investment. Its mandate is consumer brands in the middle of the market, companies too small for a strategic buyer to chase and too established for venture money to price.
Unilever’s chief executive, Hein Schumacher, who took over in 2023, has spent his tenure pulling the company toward roughly 30 power brands and separating the ice-cream business, which now trades on its own. Divestitures like Welly are the quieter half of that program. They rarely move the share price, and they rarely get announced with much ceremony.
People familiar with the sale process said Unilever ran a targeted process, approaching a short list of consumer funds rather than opening a broad auction. That approach tends to produce a faster signing and a lower headline price, and it keeps the brand’s retail partners from learning about the change from a press release.
Analysts said the sale fits a pattern investors have been asking for. Unilever’s problem has been growth, not scale, and a portfolio of small labels collected over a decade added complexity without adding much revenue. Getting out of a sub-scale brand costs less management attention than fixing it.
The buyer’s arithmetic is different. For a fund of Forward’s size, a brand with national retail distribution and a founder who can still be reached by phone is a manageable bet. The firm can hold the asset for five to seven years, put capital behind marketing, and sell into a strategic buyer later if the growth returns.
Dealmaking in consumer has been slow. Strategic buyers have been cautious about paying for growth they cannot verify, and financing costs have made larger debt-financed deals harder to structure. That has left the middle of the market to specialist funds, which can write checks of $50 million to $200 million without needing syndicated debt.
First-aid is also a category that behaves differently from most consumer goods. The products are replenished rather than aspirational, bought in small amounts and rarely postponed. Retailers have been expanding private-label lines in the aisle, which puts pressure on a premium brand that depends on packaging and placement to justify its price.
That is the open question in this deal. Welly’s premium was built on design at a moment when the aisle was uniformly beige, and design advantage is easy to copy. Copying it costs a competitor a season, not a decade.
People close to Forward said the plan is to widen distribution beyond the chain accounts Welly already has and to push further into the broader first-aid assortment, where the brand’s name carries more weight than its packaging does. The firm declined to discuss specific plans or the price.
For Ryan, the next chapter is advisory work and whatever he starts next. He has now sold two companies to the same buyer, and the second is moving to a fund he will advise rather than run, a sequence that says as much about Unilever’s appetite as about his own.
Whether Forward can grow a bandage business faster than a consumer giant could is the question the deal now rests on. The answer will show up on the shelf, in a category where shoppers decide in about four seconds.
